Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting

Christina H. Ruhlmann*, Jørn Herrstedt

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

    Abstrakt

    For patients receiving cancer chemotherapy, the ongoing development of antiemetic treatment is of significant importance. Patients consider nausea and vomiting among the most distressing symptoms of chemotherapy, and as new antiemetics have been very successful in prevention of vomiting, agents effective against nausea have become one of the major unmet needs. The neurokinin (NK) 1 receptor antagonist aprepitant potentiates the antiemetic efficacy of the combination of a serotonin receptor antagonist and a corticosteroid. Fosaprepitant (intravenous prodrug of aprepitant) given as a single intravenous dose of 150 mg can replace the aprepitant 3-day oral regimen. This article focuses on the development and clinical application of fosaprepitant.

    OriginalsprogEngelsk
    Sider (fra-til)139-150
    Antal sider12
    TidsskriftExpert Review of Anticancer Therapy
    Vol/bind12
    Udgave nummer2
    DOI
    StatusUdgivet - 1 feb. 2012

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting' indeholder.

    Citationsformater